Grantham, Mayo, Van Otterloo & Co (GMO)
ACHN

Grantham, Mayo, Van Otterloo & Co (GMO)’s Achillion Pharmaceuticals ACHN Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-87,200
Closed -$526K – 856
2019
Q4 		$526K Sell
87,200
-3,800
-4% -$22K ﹤0.01% 590
2019
Q3 		$328K Buy
+91,000
New +$351K ﹤0.01% 666

Grantham, Mayo, Van Otterloo & Co (GMO)'s ACHN Position: Q1 2020 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 87,200 shares — an estimated $526K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in ACHN in Q3 2019 and held it in 2 quarters. The position peaked at $526K in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 87,200 Achillion Pharmaceuticals shares in Q1 2020, an estimated $526K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Achillion Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Achillion Pharmaceuticals position peaked at $526K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2020, filed 14 May 2020.